Bio-Thera And Intract Partner For Oral mAb Project

Chinese Biosimilars Specialist Licenses Soteria And Phloral Drug Delivery Technologies

 
• By Dave Wallace

Chinese biosimilars specialist Bio-Thera Solutions has struck a licensing deal with Intract Pharma that will give it access to drug delivery technologies that will be used to develop novel oral monoclonal antibody treatments for gastrointestinal inflammatory indications.

Monoclonal antibodies mabs
Bio-Thera will use Intract’s technology to develop novel oral mAbs • Source: Alamy

Chinese biosimilars developer Bio-Thera Solutions has announced plans to develop “novel oral monoclonal antibody treatments for chronic gastrointestinal inflammatory diseases,” after striking a deal with Intract Pharma that will give it access to its Soteria and Phloral drug-delivery technologies.

According to Bio-Thera, the “global collaboration and license agreement” with Intract will see Bio-Thera granted a “worldwide license to Intract’s oral biologics drug

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.